AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9782544 — intervention group
Group type: COMPARATOR
Intervention: Elastic stockings and abdominal binder
Number of subjects: 9
Study 9782544 — intervention group
Group type: COMPARATOR
Intervention: Functional electrical stimulation of the leg muscles
Number of subjects: 9
Study 7874655 — intervention group
Group type: EXPERIMENTAL
Intervention: DIB positive subjects (n=132)
Number of subjects: 171
Study 7874655 — intervention group
Group type: EXPERIMENTAL
Intervention: DIBR scoring levels
Number of subjects: 171
Study 7874655 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures of problematic behaviors, symptoms, and social adaptation
Number of subjects: 171
Study 3202391 — intervention group
Group type: EXPERIMENTAL
Intervention: Metras catheter (MC)
Number of subjects: 25
Study 3202391 — intervention group
Group type: COMPARATOR
Intervention: Conventional fiberoptic bronchoscope (FB)
Number of subjects: 25
Study 12066096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 36
Study 12066096 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 36
Study 30554600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% twice daily
Number of subjects: 247
Study 30554600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream 1% once daily
Number of subjects: 247
Study 30554600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5% twice daily
Number of subjects: 247
Study 30554600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream 0.5% once daily
Number of subjects: 247
Study 30554600 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream twice daily
Number of subjects: 247
Study 30554600 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream once daily
Number of subjects: 247
Study 30554600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof cream
Number of subjects: 247
Study 29635949 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 0
Study 29635949 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study 29635949 — intervention group
Group type: COMPARATOR
Intervention: Inactive control (nonattenders)
Number of subjects: 0
Study 26628383 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m²)
Number of subjects: 1588
Study 26628383 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (n=814)
Number of subjects: 1588
Study 26628383 — intervention group
Group type: COMPARATOR
Intervention: Normal BMI (18.5-25 kg/m²)
Number of subjects: 1588
Study 26628383 — intervention group
Group type: COMPARATOR
Intervention: Overweight (BMI 25-30 kg/m²)
Number of subjects: 1588
Study 26628383 — intervention group
Group type: COMPARATOR
Intervention: Obese (BMI ≥30 kg/m²)
Number of subjects: 1588
Study 24885486 — intervention group
Group type: EXPERIMENTAL
Intervention: HNCP (H&N Cancer Survivor Self‐management Care Plan) delivered by trained oncology nurses
Number of subjects: 120
Study 24885486 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 24885486 — intervention group
Group type: COMPARATOR
Intervention: Written resource (information)
Number of subjects: 120
Study 23160920 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (single dose)
Number of subjects: 10
Study 23160920 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (multiple doses)
Number of subjects: 10
Study 23160920 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablet (both single and multiple doses)
Number of subjects: 10
Study 20521399 — intervention group
Group type: EXPERIMENTAL
Intervention: ASUMA Project intervention group
Number of subjects: 135
Study 20521399 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 18630653 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicarious intergroup contact
Number of subjects: 0
Study 18630653 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicarious intergroup contact with authority figure support
Number of subjects: 0
Study 18630653 — intervention group
Group type: COMPARATOR
Intervention: No contact condition
Number of subjects: 0
Study 15776832 — intervention group
Group type: EXPERIMENTAL
Intervention: terazosine (5 mg/day, n = 29)
Number of subjects: 51
Study 15776832 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 22)
Number of subjects: 51
Study 12431195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium difficile-specific IgG (CDIgG) measurement using ELISA in atopic wheezy infants
Number of subjects: 390
Study 12431195 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-atopic, no history of wheeze)
Number of subjects: 390
Study 10512904 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptiganel HCl (4.5 mg bolus followed by 0.75 mg/h infusion for 12 hours)
Number of subjects: 46
Study 10512904 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptiganel HCl (6 mg bolus followed by 1 mg/h infusion)
Number of subjects: 46
Study 10512904 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptiganel HCl (7.5 mg bolus)
Number of subjects: 46
Study 10512904 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptiganel HCl (3 mg, 4.5 mg, 6 mg, 7.5 mg bolus doses)
Number of subjects: 46
Study 10512904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7860749 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg draflazine
Number of subjects: 12
Study 7860749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7860749 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine dosages (0.15, 0.5, 1.5, 5, 15, and 50 micrograms/100 ml forearm per min)
Number of subjects: 12
Study 1781051 — intervention group
Group type: EXPERIMENTAL
Intervention: Gitadyl (a herbal medicine containing 110 mg fever few, 90 mg American aspen, and 60 mg milfoil)
Number of subjects: 35
Study 1781051 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (Ibumetin) 1,200 mg
Number of subjects: 35
Study 1781051 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (Ibumetin)
Number of subjects: 35
Study 6161534 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylprocainamide (NAPA)
Number of subjects: 11
Study 6161534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31825471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (titrated to 97/103 mg twice daily)
Number of subjects: 881
Study 31825471 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from enalapril to sacubitril/valsartan after week 8
Number of subjects: 881
Study 31825471 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital initiation of sacubitril/valsartan
Number of subjects: 881
Study 31825471 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (titrated to target dose, 10 mg twice daily)
Number of subjects: 881
Study 30833321 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training resource for estimating survival in palliative care patients.
Number of subjects: 128
Study 30833321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to the online training resource).
Number of subjects: 128
Study 28169450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented prostheses (three designs)
Number of subjects: 0
Study 28169450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless prosthesis
Number of subjects: 0
Study 28169450 — intervention group
Group type: COMPARATOR
Intervention: Hip resurfacing prosthesis
Number of subjects: 0
Study 28169450 — intervention group
Group type: EXPERIMENTAL
Intervention: All prostheses except hip resurfacing
Number of subjects: 0
Study 27151378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CD34+ stem cells (1×10^5 CD34/kg body weight)
Number of subjects: 167
Study 27151378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CD34+ stem cells (5×10^5 CD34/kg)
Number of subjects: 167
Study 27151378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 27151378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CD34+ stem cells
Number of subjects: 167
Study 27151378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CD34+ stem cells
Number of subjects: 167
Study 27151378 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 167
Study 24416197 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic saline/told hypertonic saline
Number of subjects: 48
Study 24416197 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic saline+lidocaine/told hypertonic saline
Number of subjects: 48
Study 24416197 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic saline+placebo/told hypertonic saline+pain killer
Number of subjects: 48
Study 24416197 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic saline+lidocaine/told hypertonic saline+pain killer
Number of subjects: 48
Study 22009072 — intervention group
Group type: EXPERIMENTAL
Intervention: High n-3 fatty acids
Number of subjects: 598
Study 22009072 — intervention group
Group type: EXPERIMENTAL
Intervention: High MN intervention
Number of subjects: 598
Study 19512866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (100 ng/ml) and Clonidine (2.5 microg/kg)
Number of subjects: 10
Study 19512866 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (100 ng/ml) and Alfentanil (150 ng/ml)
Number of subjects: 10
Study 19512866 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study 17472199 — intervention group
Group type: EXPERIMENTAL
Intervention: Social phobia group
Number of subjects: 54
Study 17472199 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression group
Number of subjects: 54
Study 17472199 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 54
Study 14747165 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol
Number of subjects: 104
Study 14747165 — intervention group
Group type: COMPARATOR
Intervention: Placebo (expectant management)
Number of subjects: 104
Study 12324985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 12324985 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 0
Study 12324985 — intervention group
Group type: EXPERIMENTAL
Intervention: New patterns of insulin use
Number of subjects: 0
Study 9649911 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing against an inspiratory threshold (40% of maximal inspiratory pressure)
Number of subjects: 16
Study 8088015 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 42
Study 8088015 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital
Number of subjects: 42
Study 8088015 — intervention group
Group type: COMPARATOR
Intervention: Control (spontaneous drowsing)
Number of subjects: 42
Study 2770513 — intervention group
Group type: EXPERIMENTAL
Intervention: Disk‐Criminator
Number of subjects: 38
Study 2770513 — intervention group
Group type: EXPERIMENTAL
Intervention: three‐prong Aesthesiometer
Number of subjects: 38
Study 2770513 — intervention group
Group type: EXPERIMENTAL
Intervention: paper clip
Number of subjects: 38
Study 1202932 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 35
Study 1202932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electro-acupuncture)
Number of subjects: 35
Study 31271573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenectomy
Number of subjects: 24
Study 31271573 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior oblique hang-back recession
Number of subjects: 24
Study 31271573 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior oblique suture spacers
Number of subjects: 24
Study 29178731 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush with tapered bristles (Oral‐B Super Thin Indicator toothbrush, OM159)
Number of subjects: 103
Study 29178731 — intervention group
Group type: COMPARATOR
Intervention: Marketed control toothbrush (Study 1: Oral‐B Complete Clean & Sensitive toothbrush; Study 2: Crest Pro‐Health Complete 7 Brush 35 toothbrush)
Number of subjects: 103
Study 29178731 — intervention group
Group type: COMPARATOR
Intervention: Marketed control toothbrush (Crest Pro‐Health Complete 7 Brush 35 toothbrush)
Number of subjects: 103
Study 26212490 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 39
Study 26212490 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 39
Study 23714676 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 21-phosphate encapsulated into autologous erythrocytes (n = 19)
Number of subjects: 37
Study 23714676 — intervention group
Group type: COMPARATOR
Intervention: Sham infusions (n = 18)
Number of subjects: 37
Study 21436212 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone plus vitamin E (group 2)
Number of subjects: 20
Study 21436212 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (group 1)
Number of subjects: 20
Study 18580547 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 11237
Study 18580547 — intervention group
Group type: COMPARATOR
Intervention: Various types of NSAIDs including COX-2 NSAIDs
Number of subjects: 11237
Study 18580547 — intervention group
Group type: COMPARATOR
Intervention: COX-2 NSAIDs
Number of subjects: 11237
Study 18580547 — intervention group
Group type: COMPARATOR
Intervention: Selective COX-2 inhibitors
Number of subjects: 11237
Study 16998290 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg i.v. initially and 1 mg i.v. every 4 hours for 3 days)
Number of subjects: 88
Study 16998290 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (continuous infusion of 25 microgram/h for 5 days)
Number of subjects: 88
Study 12942351 — intervention group
Group type: EXPERIMENTAL
Intervention: Apicoectomy only (Group II)
Number of subjects: 51
Study 12942351 — intervention group
Group type: COMPARATOR
Intervention: Control (Group I)
Number of subjects: 51
Study 12942351 — intervention group
Group type: EXPERIMENTAL
Intervention: Apicoectomy with retrograde seal using Ketac Fil (Group III)
Number of subjects: 51
Study 11074150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal nicotine spray (1-2mg)
Number of subjects: 11
Study 11074150 — intervention group
Group type: COMPARATOR
Intervention: Active placebo spray of oleoresin of pepper
Number of subjects: 11
Study 9436145 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 18
Study 9436145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spinal manipulation)
Number of subjects: 18
Study 8513038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (FF) 60 mg orally
Number of subjects: 8
Study 8513038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2877397 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant radiotherapy
Number of subjects: 230
Study 2877397 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 230
Study 30704429 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic foods complementary diet (lower protein content, increased fruits, vegetables, and fish)
Number of subjects: 0
Study 30704429 — intervention group
Group type: COMPARATOR
Intervention: Currently recommended Swedish complementary diet
Number of subjects: 0
Study 26952318 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional voice rehabilitation (SG)
Number of subjects: 20
Study 26952318 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 20
Study 26860800 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng (3.0 g/day)
Number of subjects: 62
Study 26860800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24176646 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+MCT
Number of subjects: 52
Study 24176646 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 52
Study 23156978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbinafine solution made with crushed tablet
Number of subjects: 6
Study 23156978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbinafine solution made with raw drug powder
Number of subjects: 6
Study 19029416 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured QOL diary (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and the related lung cancer module LC13) completed weekly for 16 weeks
Number of subjects: 115
Study 19029416 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 115
Study 17545356 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone dosage of 0.11 IU/kg body weight per day
Number of subjects: 63
Study 17545356 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone dosage of 0.21 IU/kg body weight per day
Number of subjects: 63
Study 17545356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 12921456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier sucking before milk feeding
Number of subjects: 36
Study 12921456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pacifier before feeding)
Number of subjects: 36
Study 11000734 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM subgroup (lansoprazole + amoxicillin + metronidazole)
Number of subjects: 100
Study 11000734 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC subgroup (lansoprazole + metronidazole + clarithromycin)
Number of subjects: 100
Study 11000734 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC subgroup (lansoprazole + amoxicillin + clarithromycin)
Number of subjects: 100
Study 11000734 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM subgroup with initial metronidazole resistance
Number of subjects: 100
Study 11000734 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC subgroup with initial metronidazole resistance
Number of subjects: 100
Study 11000734 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC subgroup with initial metronidazole susceptibility
Number of subjects: 100
Study 11000734 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM and MLC subgroups (metronidazole)
Number of subjects: 100
Study 11000734 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC and MLC subgroups (clarithromycin)
Number of subjects: 100
Study 8834030 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg/day) and ursodeoxycholic acid
Number of subjects: 22
Study 8834030 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid alone
Number of subjects: 22
Study 1468087 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium chloride solution
Number of subjects: 12
Study 1468087 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release magnesium chloride tablets
Number of subjects: 12
Study 1468087 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium gluconate tablets
Number of subjects: 12
Study 1468087 — intervention group
Group type: COMPARATOR
Intervention: All supplements
Number of subjects: 12
Study 6378439 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 18
Study 6378439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3002735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam with ampicillin (1 gm with 1 gm)
Number of subjects: 92
Study 3002735 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 gm)
Number of subjects: 92
Study 3002735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam with ampicillin
Number of subjects: 92
Study 3002735 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 92
Study 3002735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 30463622 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Number of subjects: 600
Study 30463622 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity NPPV
Number of subjects: 600
Study 28919843 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine (3 g/dose)
Number of subjects: 6
Study 28919843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 25926507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei 431 (≥10^9 CFU)
Number of subjects: 1104
Study 25926507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1104
Study 23053130 — intervention group
Group type: COMPARATOR
Intervention: Continuous Resistance Training (CTR)
Number of subjects: 14
Study 23053130 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic Resistance Training (PTR)
Number of subjects: 14
Study 20657774 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured case record form (CRF) interviews
Number of subjects: 725
Study 20657774 — intervention group
Group type: EXPERIMENTAL
Intervention: Coital diaries (CD)
Number of subjects: 725
Study 20657774 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews (IDI)
Number of subjects: 725
Study 20657774 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangulation model
Number of subjects: 725
Study 18260773 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Flash
Number of subjects: 202
Study 18260773 — intervention group
Group type: COMPARATOR
Intervention: Accu-Chek Advantage
Number of subjects: 202
Study 18260773 — intervention group
Group type: COMPARATOR
Intervention: Accu-Chek Compact Plus
Number of subjects: 202
Study 18260773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascensia Contour
Number of subjects: 202
Study 18260773 — intervention group
Group type: COMPARATOR
Intervention: BD Logic
Number of subjects: 202
Study 18260773 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Flash (second group)
Number of subjects: 202
Study 18260773 — intervention group
Group type: COMPARATOR
Intervention: All meters
Number of subjects: 202
Study 18260773 — intervention group
Group type: COMPARATOR
Intervention: Accu-Chek Advantage, Accu-Chek Compact Plus, BD Logic
Number of subjects: 202
Study 16364566 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths based case management
Number of subjects: 245
Study 16364566 — intervention group
Group type: COMPARATOR
Intervention: Passive referral
Number of subjects: 245